---
title: "Cytomx Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 10.26 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285611287.md"
datetime: "2026-05-07T20:22:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285611287.md)
  - [en](https://longbridge.com/en/news/285611287.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285611287.md)
generator: "portal-rs"
---

# Cytomx Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 10.26 M

Revenue: As of FY2026 Q1, the actual value is USD 10.26 M, beating the estimate of USD 4.683 M.

EPS: As of FY2026 Q1, the actual value is USD -0.1.

EBIT: As of FY2026 Q1, the actual value is USD -21.16 M.

### Q1 2026 Financial Results

#### Total Revenue

\[CytomX Therapeutics, Inc.\] reported total revenue of $10.3 million for the first quarter ended March 31, 2026, a decrease compared to $50.9 million for the first quarter of 2025 . This decline was primarily due to the completion of performance obligations in collaborations during 2025 .

#### Operational Expenses

Total operating expenses increased to $29.9 million for Q1 2026 from $28.3 million in Q1 2025 . **Research and Development Expenses**: Rose to $19.2 million in Q1 2026, up from $18.9 million in Q1 2025 . **General and Administrative Expenses**: Increased to $10.7 million in Q1 2026 from $9.4 million in Q1 2025 .

#### Income/Loss from Operations

The company reported an income loss from operations of - $19.672 million for Q1 2026, a shift from an income of $22.621 million in Q1 2025 .

#### Interest Income

Interest income for Q1 2026 was $1.490 million, an increase from $0.955 million in Q1 2025 .

#### Net Income/Loss Attributable to Common Stockholders

Net loss attributable to common stockholders was - $18.248 million for Q1 2026, compared to a net income of $23.525 million for Q1 2025 .

### Balance Sheet Highlights (as of March 31, 2026)

#### Cash, Cash Equivalents and Investments

Cash, cash equivalents and investments totaled $346.7 million, significantly up from $137.1 million as of December 31, 2025 . This increase includes $234.2 million in net proceeds from an equity follow-on offering completed in March 2026, which generated gross proceeds of $250 million .

#### Total Assets

Total assets were $359,358 thousand as of March 31, 2026, compared to $151,566 thousand as of December 31, 2025 .

#### Total Liabilities

Total liabilities decreased to $39,414 thousand as of March 31, 2026, from $52,558 thousand as of December 31, 2025 .

#### Total Stockholders’ Equity

Total stockholders’ equity increased to $319,944 thousand as of March 31, 2026, from $99,008 thousand as of December 31, 2025 .

### Outlook

\[CytomX Therapeutics, Inc.\] expects its cash runway to extend to at least the second half of 2028 . Additional Phase 1 Varseta-M data is anticipated in the second half of 2026 to inform monotherapy dose selection and potential registrational trial design in late-line colorectal cancer . The company plans FDA interactions in 2026 to align on the potential first registrational study for Varseta-M monotherapy in advanced colorectal cancer, aiming to start in the first half of 2027, and projects initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma by the end of 2026 .

### Related Stocks

- [CTMX.US](https://longbridge.com/en/quote/CTMX.US.md)

## Related News & Research

- [CytomX highlights Varseta-M EpCAM Topo-1 ADC data in late-line metastatic colorectal cancer presentation](https://longbridge.com/en/news/298356652.md)
- [CTMX: Varseta-M and CX-801 advance in clinical trials, targeting major unmet needs in oncology](https://longbridge.com/en/news/298355576.md)
- [CTMX: Lead ADC shows robust efficacy in late-line CRC, with pivotal study and new data expected this year](https://longbridge.com/en/news/298482685.md)
- [Weekly Recap: 1.5M-share inducement grant and furnished Form 8-K PSU award](https://longbridge.com/en/news/298207980.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**